Cargando…

Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)

BACKGROUND: Patients with advanced gastrointestinal stromal tumours (GISTs) resistant to the tyrosine kinase inhibitors imatinib and sunitinib may be treated with regorafenib, which resulted in a median progression-free survival (PFS) of 4.8 months in the GRID trial. Also, pazopanib, another tyrosin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eriksson, M., Reichardt, P., Joensuu, H., Krarup-Hansen, A., Hagberg, O., Hohenberger, P., Hagberg, H., Hansson, L., Foukakis, T., Pulkkanen, K., Bauer, S., Goplen, D., Blach Rossen, P., Sundby Hall, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287147/ https://www.ncbi.nlm.nih.gov/pubmed/34271307 http://dx.doi.org/10.1016/j.esmoop.2021.100217

Ejemplares similares

Transcriptional analysis of the cell division-related ssg genes in Streptomyces coelicolor reveals direct control of ssgR by AtrA
por: Kim, Songhee H., et al.
Publicado: (2015)

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial
por: Musa, Ahmed, et al.
Publicado: (2012)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

Configuring Juniper Networks NetScreen and SSG Firewalls
por: Cameron, Rob
Publicado: (2006)

Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2019)

The SsgA-like proteins in actinomycetes: small proteins up to a big task
por: Traag, Bjørn A., et al.
Publicado: (2008)

Fibrinogen‐like protein 2 in gastrointestinal stromal tumour
por: Pulkka, Olli‐Pekka, et al.
Publicado: (2022)

Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study
por: Hall, Kirsten Sundby, et al.
Publicado: (2020)

Site-specific genomic (SSG) and random domain-localized (RDL) mutagenesis in yeast
por: Gray, Misa, et al.
Publicado: (2004)

Endophytic Burkholderia sp. SSG as a potential biofertilizer promoting boxwood growth
por: Kong, Ping, et al.
Publicado: (2020)

Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient(®) in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)
por: Pink, Daniel, et al.
Publicado: (2021)

SLUG transcription factor: a pro-survival and prognostic factor in gastrointestinal stromal tumour
por: Pulkka, Olli-Pekka, et al.
Publicado: (2017)

Reliability of Margin Assessment after Surgery for Extremity Soft Tissue Sarcoma: The SSG Experience
por: Trovik, Clement S., et al.
Publicado: (2012)

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG‐RMS2005 study
por: Terwisscha van Scheltinga, Sheila E. J., et al.
Publicado: (2020)

Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
por: Joensuu, Heikki, et al.
Publicado: (2014)

Complete genome sequence of a boxwood endophyte Burkholderia sp. SSG with broad biotechnological application potential
por: Kong, Ping, et al.
Publicado: (2020)

Ectopic positioning of the cell division plane is associated with single amino acid substitutions in the FtsZ-recruiting SsgB in Streptomyces
por: Xiao, Xiansha, et al.
Publicado: (2021)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
por: Ihle, Michaela Angelika, et al.
Publicado: (2018)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing Sarcoma
por: Attia, Steven, et al.
Publicado: (2015)

Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours
por: Ahn, H K, et al.
Publicado: (2013)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
por: Wilding, Christopher P, et al.
Publicado: (2019)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Pazopanib and Statin-Induced Rhabdomyolysis
por: Logue, Jennifer M., et al.
Publicado: (2017)

Phototoxic Reaction Induced by Pazopanib
por: Udompanich, Siriorn, et al.
Publicado: (2018)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
por: Katz, D., et al.
Publicado: (2016)

The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure
por: Krens, Stefanie D., et al.
Publicado: (2021)

Therapy with Sodium Stibogluconate in Stearylamine-Bearing Liposomes Confers Cure against SSG-Resistant Leishmania donovani in BALB/c Mice
por: Roychoudhury, Jayeeta, et al.
Publicado: (2011)

Genomic complexity in pediatric synovial sarcomas (Synobio study): the European pediatric soft tissue sarcoma group (EpSSG) experience
por: Orbach, Daniel, et al.
Publicado: (2018)

Comparative genomic analysis of Paenibacillus sp. SSG-1 and its closely related strains reveals the effect of glycometabolism on environmental adaptation
por: Xu, Hui, et al.
Publicado: (2017)

Pazopanib radio-sensitization of human sarcoma tumors
por: Wang, Feng, et al.
Publicado: (2018)

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis
por: Fauster, A, et al.
Publicado: (2015)

Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib
por: Vyse, Simon, et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

A Phase I/II Clinical Trial of Belinostat (PXD101) in Combination with Doxorubicin in Patients with Soft Tissue Sarcomas
por: Vitfell-Rasmussen, Joanna, et al.
Publicado: (2016)

The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor
por: Brinch, Charlotte Margareta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b755mb17i0oc7hqafou5jdeq4q